Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently ...
14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and ...
HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) will publicly present, for the first time, clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, in relapsed/refractory ...
VMT01 is a MC1R-targeted RPT that can be radiolabeled with either (203) Pb for patient selection and dosimetry assessments, or (212) Pb for alpha particle therapy.
WALTHAM, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Life Edit ® Therapeutics Inc., an ElevateBio ® company focused on next-generation gene editing technologies and therapeutics, today announced the ...
Immix Biopharma, Inc. has announced that interim data from its Phase 1/2 NEXICART-2 trial of the CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis will be presented at the 2025 American ...
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...
ACNP abstracts are available on the conference website and the Company’s poster will be available on the Centessa website at https://investors.centessa.com/events-presentations after the poster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results